Anticancer Effect and Mechanism of Plumbagin on Lewis Lung Carcinoma in Vitro and in Vivo
LIU Fang-fang1,2b, XIE Jun-ping2a*, LI Feng-yuan1, GUO Xiao-lin2a
1. Department of Respiratory Disease, The Third Affiliated Hospital of Nanchang University, Nanchang 330000, China; 2a.Department of Respiratory Disease, 2b. The Key Molecular Medicine Laboratory of Jiangxi Province, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China
Abstract��OBJECITVE To study the inhibitive effect of plumbagin on Lewis lung cancer. METHODS Cell proliferation was determined by CCK8 assay. Apoptosis was determined by flow cytometry. The expression of Bcl-2 and VEGF protein was studied by Western blot assay. The model of C57BL/6 mice bearing Lewis lung cancer was established by subcutaneous seeding of Lewis lung cancer cells, and randomly divided into 5 groups (n=6). Tumor-bearing mice were injected with normal saline, plumbagin(low, medium, high dose) or cyclophosphamide (CTX) in each group. The tumor volume was measured. All mice were sacrificed on Day 22nd under aseptic condition for the tumor collection. The transplanted tumors were weighed for calculation of the tumor inhibition rate; Immunohistochemical method was applied to assessing the VEGF expression in tumor tissue. RESULTS CCK-8 assay showed that plumbagin had an obvious inhibition on Lewis lung carcinoma cells line in a dose-dependent manner(r=0.953, P<0.05). Plumbagin significantly increased cell apoptosis rate(P<0.05). The protein levels of Bcl-2 and VEGF were significantly reduced by plumbagin (0, 2.5, 5, 10 ��mol��L-1) treatment(P<0.05). In plumbagin(low, medium, high dose) groups and CTX group, the tumour volume, tumour weight and the expression of VEGF were significantly less than those in the control group (P<0.05). CONCLUSION The plumbagin effectively inhibits Lewis lung carcinoma cells proliferation and tumor growth of Lewis lung carcinoma cells in mice. The mechanism involved is down-regulating the expression of Bcl-2 ,VEGF and inducing cell apoptosis.
������, л��ƽ, ����Ԫ, ������. �����������⿹Lewis�ΰ���Ч���������о�[J]. �й�ҩѧ��־, 2017, 52(7): 581-586.
LIU Fang-fang, XIE Jun-ping, LI Feng-yuan, GUO Xiao-lin. Anticancer Effect and Mechanism of Plumbagin on Lewis Lung Carcinoma in Vitro and in Vivo. Chinese Pharmaceutical Journal, 2017, 52(7): 581-586.
GEBAUER F, GELIS S, ZANDER H, et al. Tenascin-C serum levels and its prognostic power in non-small cell lung cancer[J]. Oncotarget, 2016, 7(15):20945-20952.
[2]
HAFEEZ B B, ZHONG W, MUSTAFA A, et al. Plumbagin inhibits prostate cancer development in TRAMP mice via targeting PKCepsilon, Stat3 and neuroendocrine markers[J]. Carcinogenesis, 2012, 33(12):2586-2592.
[3]
NAIR S, NAIR R R, SRINIVAS P, et al. Radiosensitizing effects of plumbagin in cervical cancer cells is through modulation of apoptotic pathway[J]. Mol Carcinog, 2008, 47(1):22-33.
[4]
SANDUR S K, PANDEY M K, SUNG B, et al. 5-hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1:potential role in chemosensitization[J]. Mol Cancer Res, 2010, 8(1):107-118.
[5]
GOMATHINAYAGAM R, SOWMYALAKSHMI S, MARDHATILLAH F, et al. Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells[J]. Anticancer Res, 2008, 28(2A):785-792.
[6]
SUMSAKUL W, CHAIJAROENKUL W, NA-BANGCHANG K. In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes[J]. Asian Pac J Trop Med, 2015, 8(11):914-918.
[7]
ITOIGAWA M, TAKEYA K, FURUKAWA H. Cardiotonic action of plumbagin on guinea-pig papillary muscle[J]. Planta Med, 1991, 57(4):317-319.
[8]
TAN M X, WANG H S, CHEN Z F, et al. Advances in studies on chemical constituents and pharmacological activities of Plumbago zeylanica[J]. Chin Tradit Herb Drugs(�в�ҩ), 2007,38(2):289-293.
[9]
ZHAO Y L, LU D P. Effects of plumbagin on the human acute promyelocytic leukemia cells in vitro[J]. J Exper Hematol, 2006,14(2):208-211.
[10]
LIU C, LIU Y, YAN X Y. Effects of plumbagin on the human breast cancer cell mda����mb-23 1 in vitro[J]. West China J Pharm Sci(����ҩѧ��־), 2008,23(1):42-44.
[11]
XU K H, LU D P. Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo[J]. Leuk Res, 2010, 34(5):658-665.
[12]
MANU K A, SHANMUGAM M K, RAJENDRAN P, et al. Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4[J]. Mol Cancer, 2011, 10:107.
[13]
YAN C H, LI F, MA Y C. Plumbagin shows anticancer activity in human osteosarcoma (MG-63) cells via the inhibition of S-Phase checkpoints and down-regulation of c-myc[J]. Int J Clin Exp Med, 2015, 8(8):14432-14439.
[14]
SANDUR S K, ICHIKAWA H, SETHI G, et al. Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) suppresses NF-kappa B activation and NF-kappaB-regulated gene products through modulation of p65 and IkappaBalpha kinase activation, leading to potentiation of apoptosis induced by cytokine and chemotherapeutic agents[J]. J Biol Chem, 2006, 281(25):17023-17033.
[15]
AZIZ M H, DRECKSCHMIDT N E, VERMA A K. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer[J]. Cancer Res, 2008, 68(21):9024-9032.
[16]
KUO P L, HSU Y L, CHO C Y. Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells[J]. Mol Cancer Ther, 2006, 5(12):3209-3221.
[17]
RIBATTI D. History of research on angiogenesis[J]. Chem Immunol Allergy, 2014, 99:1-14.
[18]
CRAWFORD Y, FERRARA N. VEGF inhibition:insights from preclinical and clinical studies[J]. Cell Tissue Res, 2009, 335(1):261-269.
[19]
FENG Y F, LEI J, FU D X. Vascular endothelial growth factor inhibitors--bevacizumab[J]. Chin Pharm J(�й�ҩѧ��־), 2005,40(19):1519-2520.
[20]
ZHANG Q, BINDOKAS V, SHEN J, et al. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents[J]. Mol Cancer Ther, 2011, 10(7):1173-1184.
2017, Vol. 52 
